Investor Ideas Potcasts, Cannabis News and Stocks on the Move (CSE: CNNA) (OTCQB: GBLX) (TSX: VFF) (NASDAQ: VFF) (OTC: DXBRF) (CSE: THC)
Delta, Kelowna, BC - June 11, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today's edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Investor Ideas Potcasts, #Cannabis News and Stocks on the Move (CSE: $CNNA.C) (OTCQB: $GBLX) (TSX: $VFF.TO) (NASDAQ: $VFF) (OTC: $DXBRF) (CSE: $THC.C)
Today's podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "potcasts", looking at cannabis news, stocks to watch as well as insights from thought leaders and experts.
We're back from New York and ready to look at a few early announcements.
Before getting into announcements, The 22nd edition of The Sanofi Canada Healthcare Survey uncovered gaps in knowledge that can serve to help guide decision-making among employers who provide health benefit plans to employees. A persistent gap is employers' underestimation of the presence of chronic disease in their workforce, which suggests they may also underestimate the negative impact of unmanaged disease on productivity.
"Providers of workplace health benefit plans can use these results to help drive new benefit offerings and wellness initiatives that focus on supporting plan members with chronic disease," says Michael Mullette, President and CEO of Sanofi Canada. "The past few years have seen positive growth in supports for mental health, which can serve as a model for other major chronic conditions such as diabetes and cardiovascular disease."
The Sanofi Canada Healthcare Survey also reveals employees' and employers' opinions on numerous other timely topics, including precision medicine, targeted health messaging, national Pharmacare and medical cannabis. The full report is available from Sanofi Canada's website at www.sanofi.ca/en/about-us/sanofi-canada-healthcare-survey.
Growing urgency to do more for chronic disease
- 54% of plan members have been diagnosed with at least one chronic disease or condition, increasing to 69% among those aged 55 to 64.
- Plan sponsors estimate that 39% of their workforce has a chronic condition.
- When chronic pain is added to the equation, 67% of employees have a condition that can impact productivity and lead to repeated absences from the workplace.
- 87% of employees with a chronic condition would like to know more about their condition and how to treat it.
- 82% of employers would like their benefit plan to do more to support employees with chronic conditions.
Changing menu for health benefits
- 74% of employees would consent to pharmacogenetic testing so that physicians can prescribe medications that are most likely to work well for them (referred to as precision medicine or personalized medicine); 65% of employers are interested in providing coverage for pharmacogenetic testing.
- 65% of employees would consent to receive health information based on their personal use of benefits; 74% of employers would like their benefit plan's insurance carrier to send such targeted health messaging to employees.
- 45% of employers agree medical cannabis should be covered by their workplace health benefit plan, up from 34% in 2018; 64% of employees believe medical cannabis should be covered.
Workplace drug plans misunderstood
- Employees and employers significantly underestimate the number of drugs covered by workplace drug plans, and overestimate the number of drugs covered by provincial drug plans.
- 77% of employees and 52% of employers have low or no knowledge about a possible national Pharmacare program in Canada.
- Levels of support are high among employees (87%) and employers (84%) for a Pharmacare that fills gaps in coverage for Canadians who have no insurance or are underinsured, and does not affect workplace drug plans.
CannaOne Technologies (CSE: CNNA) announced that it has easily garnered well in excess of the initial 10,000 member sign-up target it had set for the BWell CBD Online Marketplace 10 day pre-launch referral campaign. The pre-launch campaign adopted a referral based sign-up initiative to ensure the marketplace would possess the foundation of a truly authentic community of highly engaged customers. There was no better way to make certain those are the types of members registering for the marketplace, that to work from the premise that the most powerful and effective way to introduce a new company to a diverse clientele was by way of a credible referral. The referral campaign will remain an on-going business strategy and sign-ups are expected to continue to grow exponentially. The BWell CBD Online Marketplace will be launching later this month with a significant customer base eager to purchase the plethora of premium CBD products to be offered.
Stated Solomon Riby Williams, CEO: "We saw the pre-launch undertaking as a way to not only make people feel special, but at the same time to educate them to the advantages and benefits of the BWell marketplace. Education is everything in this industry and we exert a lot of effort towards assisting our new customers to make well-informed buying decisions, that render the best solutions for their own individual needs. We also understand how important it is for customers to be introduced to BWell through a referral from someone they know; a friend, or a family member or even by digital word of mouth. Our goal was to make sure to garner and build a solid community of membership in advance of the marketplace being officially open for business, and with that goal in mind, we are ecstatic that the reception for membership to the pre-launch has surpassed all our expectations as we have already outdone our target of 10,000 sign-ups for the launch of BWell later this month".
GB Sciences, Inc. (OTCQB:GBLX) today announced it has obtained an exclusive license to formulate, manufacture, and sell cannabis-infused oral thin films through its MME-licensed subsidiaries and affiliates GB Sciences Louisiana, LLC, GB Sciences Nevada, LLC, and GB Sciences Las Vegas, LLC, under US Patent Number 10,265,362 B2 issued April 2019.
GB Sciences' new oral thin films will be sold in Louisiana and Nevada, reflecting the company's commitment to providing advanced medical cannabis products. Oral thin films are rapidly gaining popularity due to their efficacy, convenience, and discreteness, and sales are increasing rapidly in major cannabis markets including California and Colorado.
"Securing this patented technology will allow us to get our patent-pending active pharmaceutical ingredients into the hands of patients in Louisiana and Nevada right away. This is great for patients, who have access to an entirely new way to consume precisely-dosed cannabis without the potential drawbacks of other delivery systems. And nobody else has this technology - making it a good mechanism for GB Sciences to further monetize its considerable intellectual property portfolio," explained John Poss, CEO and Chairman of GB Sciences, Inc.
"Oral thin films are very effective, easy to use, and have many advantages over other delivery systems on the market. We can precisely dose each strip, and patients who can't swallow will have no problem taking these," said Dr. Andrea Small-Howard, Chief Science Officer and Director of GB Sciences. "The active ingredients in cannabis, such as cannabinoids and terpenes, are more bioavailable via oral thin films because they're absorbed directly by the cells in the mouth, then pass into the bloodstream. That means quicker delivery and more complete dosing, without some of the negatives associated with edibles."
Village Farms International, Inc. (TSX: VFF) (NASDAQ: VFF) today announced that Governor Greg Abbott has signed into law Texas House Bill 1325 (the "Texas Hemp Legislation"), which effectively legalizes the cultivation of hemp and processing of hemp and hemp-derived products, including cannabidiol (CBD) in the State.
As previously announced, in anticipation of the passage of the hemp legislation in Texas, Village Farms has begun conversion of half of its 1.3 million square foot, ultra-high-tech Permian Basin greenhouse (which utilizes the Company's proprietary GATES® technology) for cultivation of high-CBD hemp and CBD extraction. The Texas Hemp Legislation will require licenses for both the cultivation and processing of hemp and Village Farms plans to apply for the requisite licenses as soon as it is permitted to do so. No time frame has yet been provided by the State of Texas for the licensing process.
"The Governor's signing of this bill into law formalizes a significant opportunity for Village Farms as a first mover in the Texas hemp industry and will allow us to capitalize on the expected demand for premium-grade hemp grown in controlled-environment facilities for the high-end health and wellness and the pharmaceutical industries," said Michael DeGiglio, CEO, Village Farms International. "Conversion of half of Permian Basin greenhouse in West Texas for hemp production is now well underway and we look forward to commencing production as soon as possible upon Texas establishing a licensing and regulatory framework for hemp and CBD."
Dixie Brands Inc. (CSE: DIXI.U), (OTC: DXBRF) today announced that it is entering the Oklahoma medical-use cannabis market through a manufacturing, distribution and licensing agreement the Company has signed with Globus Holdings ("Globus"). Oklahoma will become the sixth state in Dixie's growing U.S. footprint.
Pursuant to the agreements, Dixie will work in conjunction with Globus to use Dixie's intellectual property, including its proprietary formulations and preparation methods as well as the associated trademarks, in the State of Oklahoma. Globus' manufacturing facility in Tulsa will make use of Dixie's proprietary formulations and proven "GMP" (good manufacturing practices) and quality control procedures. Initial products including gummies, mints, pills, vaporizers, and drinks are expected to be available beginning in the Fall of this year.
"We continue to execute on our stated priorities for 2019, and expanding into new U.S. states is at the top of that list," said Chuck Smith, President and CEO, Dixie Brands. "We are very excited to introduce Dixie products to Oklahoma. The state has embraced legal cannabis over the past year and we anticipate that our relatively early entry into the market will help establish Dixie as one of the top-selling brands."
Oklahoma has proceeded quickly to license medical marijuana patients and industry participants since voters approved medical use through a June 2018 ballot question.
According to the Oklahoma Medical Marijuana Authority, the state has approved 129,000 patients, as well as growers, processors and nearly 1,500 dispensaries. Based on recent reports from the Oklahoma Tax Commission, cannabis sales in Oklahoma exceeded $23 million in May 2019, and have been growing significantly from month to month as industry participants continue to ramp their operations.
THC BioMed Intl Ltd. (CSE: THC) announced that it is the first Canadian Licensed Producer to automate the pre-rolling of cigarettes containing 100% cannabis (the "Pure Cannabis Cigarettes"). In the same way automation changed the tobacco industry, THC BioMed is confident the automation of Pure Cannabis Cigarettes will bring meaningful changes to the current cannabis industry and its bottom line.
Pure Cannabis Cigarettes to be Introduced to Canadian Cannabis Market (CNW Group/THC BioMed)
The automated cigarette manufacturing plant has been installed at THC BioMed's flagship Acland Road location. THC will begin the production and sales of commercial-grade Pure Cannabis Cigarettes, a first in Canada.
The Pure Cannabis Cigarettes are to be packaged in lots of 3 and 20. Each Pure Cannabis Cigarette will be intended for a single-use session and will come with a commercial-grade cigarette filter. There will be no tobacco in the Pure Cannabis Cigarettes.
"We are very pleased to offer Canadians a better way of smoking cannabis, as we monitored an increase in demand for our best-selling pre-rolls, we acknowledged that it was our duty to ensure we distribute the best products possible. We are pleased to be the first cannabis producer to put filters between the cannabis we are selling, and our consumers. Filters were invented to protect the consumer and not degrade the experience. "We promise our Pure Cannabis Cigarettes will offer the same potency as our regular best-selling pre-rolls. I am predicting consumers will gravitate towards this finished type of product and the old way of rolling joints will be something of the past," said John Miller, President and CEO of THC BioMed.
Subscribe to the new cannabis podcast series:
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media